Home
NewsNewsLuna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
On March 17, 2026, healthtech innovator Luna and fertility benefits provider Kindbody announced a strategic partnership aimed at transforming women’s health through enhanced data-driven Intelligence in Fertility Care. This collaboration is designed to provide unprecedented clarity and personalisation for individuals navigating the complexities of the fertility journey.
Luna, recognised for developing advanced smart wearables, will integrate its biomarker tracking technology into Kindbody’s comprehensive fertility and family-building platform. This integration addresses a critical gap in reproductive health: the fact that intricate physiological shifts, such as changes in temperature, recovery, sleep, stress, and hormonal rhythms, primarily occur outside of a doctor's office. By bringing these daily signals into focus, the partnership offers patients a deeper understanding of their own bodies while providing Kindbody’s clinical teams with a contextual, holistic view of each individual’s health.
Amit Khatri, Founder of Luna, emphasised the human element of this technological advancement. “The conception journey is one of the most meaningful and complex chapters in a person's life, and it deserves both deep empathy and deep intelligence,” said Khatri. “By uniting Luna's continuous biomarker sensing with Kindbody's world-class clinical expertise, we are giving patients a clearer window into their bodies and giving physicians a new dimension of insight that can elevate the entire care experience. This partnership represents the future of reproductive health: connected, personalised, and profoundly human."
Kindbody, which operates a national network of signature clinics and provides virtual care, offers a wide array of services, including IVF, egg freezing, donor care, and LGBTQ+ fertility support. The company’s mission is to make high-quality reproductive care more accessible and equitable. Through this partnership, Luna’s technology, including the Luna ring, will be made available within the Kindbody ecosystem to support patients seeking a more connected path toward parenthood.
David Stern, CEO of Kindbody, highlighted the clinical value of the collaboration. “This partnership with Luna represents a significant step forward in making fertility care smarter and more personalised," said Stern. “By leveraging data-driven insights, we can better support patients and providers alike, ensuring every decision is informed, effective, and centred on the needs of those on their fertility journey."
At the heart of Luna’s contribution is LifeOS, an adaptive health operating system that interprets data from the Luna Ring to deliver real-time guidance on energy, recovery, and women’s health. Kindbody continues to expand its reach, offering benefit solutions for employers and health plans while covering everything from menopause to male fertility and holistic well-being. Together, the two companies aim to move precision health from an aspirational concept to a standard of care.
The Stork Foundation for Infertility received a record 1,076 grant applications in 2026, with data revealing that 85% of applicants have no fertility treatment coverage for the care they are pursuing. Average anticipated next treatment costs stand at 19,149 USD, with 39% having already spent more than 10,000 USD out of pocket.
Future Health, A Global Initiative by Abu Dhabi has launched the Future Health Digital Health Innovation Challenge 2026, inviting global innovators to develop AI, software, and connected technology solutions across fertility, population health, and well-being. Three finalists will share USD 105,000 at GITEX 2026, with selected solutions eligible for incubation and scale.
La Trobe University and GonGlobal have entered a strategic collaboration to develop and validate AI and digital twin technologies for ART and IVF. The partnership will build AI-driven fertility care tools, including cohort matching digital twins and deep-learning models, to predict pregnancy outcomes and support personalised clinical decision-making.
IVI Institute has announced the acquisition of The World Egg and Sperm Bank (TWESB), founded in 2004 and operating from Scottsdale, Arizona. The move expands access to reproductive solutions for patients and clinics across the United States and Australia, combining TWESB’s network of 500+ screened donors with IVI Institute’s global clinical and scientific infrastructure.
Doctors at NHS Lothian in Edinburgh have performed the UK’s first testicular tissue transplant, reimplanting tissue frozen before chemotherapy in a 19-year-old patient with a serious blood disorder. The testicular tissue transplant, only the second reported worldwide, could eventually give thousands of young boys a realistic path to future fatherhood.
Flora Fertility and Clue have announced the Flora Clue fertility partnership, connecting the first individually owned fertility insurance platform with the world’s leading women-led cycle tracking app. FLORA policyholders receive complimentary Clue Plus access, while Clue’s community of over 100 million members gains early exposure to proactive fertility financial planning.
The World Health Organization releases its first comprehensive, evidence-based global guideline for infertility prevention, diagnosis, and treatment. Addressing one in six people of reproductive age worldwide, the guideline emphasizes equity, human rights, and standardized interventions to improve access to fertility care globally.
